JP2020532967A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020532967A5 JP2020532967A5 JP2020511253A JP2020511253A JP2020532967A5 JP 2020532967 A5 JP2020532967 A5 JP 2020532967A5 JP 2020511253 A JP2020511253 A JP 2020511253A JP 2020511253 A JP2020511253 A JP 2020511253A JP 2020532967 A5 JP2020532967 A5 JP 2020532967A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally
- protein
- domain
- mutations
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000035772 mutation Effects 0.000 claims 12
- 102000004169 proteins and genes Human genes 0.000 claims 12
- 108090000623 proteins and genes Proteins 0.000 claims 12
- 210000004027 cell Anatomy 0.000 claims 10
- 108020004414 DNA Proteins 0.000 claims 8
- 108020001507 fusion proteins Proteins 0.000 claims 7
- 102000037865 fusion proteins Human genes 0.000 claims 7
- 238000000034 method Methods 0.000 claims 6
- 102000053602 DNA Human genes 0.000 claims 5
- 102000004190 Enzymes Human genes 0.000 claims 5
- 108090000790 Enzymes Proteins 0.000 claims 5
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 claims 4
- 102000055025 Adenosine deaminases Human genes 0.000 claims 4
- 102100026846 Cytidine deaminase Human genes 0.000 claims 4
- 108010031325 Cytidine deaminase Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 101710142939 Adenosine deaminase 1 Proteins 0.000 claims 2
- 108091033409 CRISPR Proteins 0.000 claims 2
- 102000000311 Cytosine Deaminase Human genes 0.000 claims 2
- 108010080611 Cytosine Deaminase Proteins 0.000 claims 2
- 108020005004 Guide RNA Proteins 0.000 claims 2
- 101710160287 Heterochromatin protein 1 Proteins 0.000 claims 2
- 108010033040 Histones Proteins 0.000 claims 2
- 102000016397 Methyltransferase Human genes 0.000 claims 2
- 108060004795 Methyltransferase Proteins 0.000 claims 2
- 241000193996 Streptococcus pyogenes Species 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 claims 2
- 230000003584 silencer Effects 0.000 claims 2
- 101710199622 tRNA-specific adenosine deaminase Proteins 0.000 claims 2
- 238000013518 transcription Methods 0.000 claims 2
- 230000035897 transcription Effects 0.000 claims 2
- 230000037426 transcriptional repression Effects 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 108010029988 AICDA (activation-induced cytidine deaminase) Proteins 0.000 claims 1
- 108010079649 APOBEC-1 Deaminase Proteins 0.000 claims 1
- 108010004483 APOBEC-3G Deaminase Proteins 0.000 claims 1
- 102100036664 Adenosine deaminase Human genes 0.000 claims 1
- 102100025976 Adenosine deaminase 2 Human genes 0.000 claims 1
- 102100040397 C->U-editing enzyme APOBEC-1 Human genes 0.000 claims 1
- 102100040399 C->U-editing enzyme APOBEC-2 Human genes 0.000 claims 1
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims 1
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims 1
- 102220605874 Cytosolic arginine sensor for mTORC1 subunit 2_D10A_mutation Human genes 0.000 claims 1
- 102100040263 DNA dC->dU-editing enzyme APOBEC-3A Human genes 0.000 claims 1
- 102100040262 DNA dC->dU-editing enzyme APOBEC-3B Human genes 0.000 claims 1
- 102100040261 DNA dC->dU-editing enzyme APOBEC-3C Human genes 0.000 claims 1
- 102100040264 DNA dC->dU-editing enzyme APOBEC-3D Human genes 0.000 claims 1
- 102100040266 DNA dC->dU-editing enzyme APOBEC-3F Human genes 0.000 claims 1
- 102100038076 DNA dC->dU-editing enzyme APOBEC-3G Human genes 0.000 claims 1
- 102100029791 Double-stranded RNA-specific adenosine deaminase Human genes 0.000 claims 1
- 102100038191 Double-stranded RNA-specific editase 1 Human genes 0.000 claims 1
- 102100024692 Double-stranded RNA-specific editase B2 Human genes 0.000 claims 1
- 102220502946 Geranylgeranyl transferase type-2 subunit alpha_D10N_mutation Human genes 0.000 claims 1
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 claims 1
- 101000720051 Homo sapiens Adenosine deaminase 2 Proteins 0.000 claims 1
- 101000964322 Homo sapiens C->U-editing enzyme APOBEC-2 Proteins 0.000 claims 1
- 101000964378 Homo sapiens DNA dC->dU-editing enzyme APOBEC-3A Proteins 0.000 claims 1
- 101000964385 Homo sapiens DNA dC->dU-editing enzyme APOBEC-3B Proteins 0.000 claims 1
- 101000964383 Homo sapiens DNA dC->dU-editing enzyme APOBEC-3C Proteins 0.000 claims 1
- 101000964382 Homo sapiens DNA dC->dU-editing enzyme APOBEC-3D Proteins 0.000 claims 1
- 101000964377 Homo sapiens DNA dC->dU-editing enzyme APOBEC-3F Proteins 0.000 claims 1
- 101000865408 Homo sapiens Double-stranded RNA-specific adenosine deaminase Proteins 0.000 claims 1
- 101000742223 Homo sapiens Double-stranded RNA-specific editase 1 Proteins 0.000 claims 1
- 101000686486 Homo sapiens Double-stranded RNA-specific editase B2 Proteins 0.000 claims 1
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 claims 1
- 101000653360 Homo sapiens Methylcytosine dioxygenase TET1 Proteins 0.000 claims 1
- 101000799048 Homo sapiens Probable inactive tRNA-specific adenosine deaminase-like protein 3 Proteins 0.000 claims 1
- 101000800426 Homo sapiens Putative C->U-editing enzyme APOBEC-4 Proteins 0.000 claims 1
- 101000657352 Homo sapiens Transcriptional adapter 2-alpha Proteins 0.000 claims 1
- 101000799160 Homo sapiens tRNA-specific adenosine deaminase 1 Proteins 0.000 claims 1
- 101000799057 Homo sapiens tRNA-specific adenosine deaminase 2 Proteins 0.000 claims 1
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 claims 1
- 102100030819 Methylcytosine dioxygenase TET1 Human genes 0.000 claims 1
- 108010057466 NF-kappa B Proteins 0.000 claims 1
- 102000003945 NF-kappa B Human genes 0.000 claims 1
- 101710141454 Nucleoprotein Proteins 0.000 claims 1
- 102100034006 Probable inactive tRNA-specific adenosine deaminase-like protein 3 Human genes 0.000 claims 1
- 102100033091 Putative C->U-editing enzyme APOBEC-4 Human genes 0.000 claims 1
- 101150023114 RNA1 gene Proteins 0.000 claims 1
- 101710122931 Replication and transcription activator Proteins 0.000 claims 1
- 102000004389 Ribonucleoproteins Human genes 0.000 claims 1
- 108010081734 Ribonucleoproteins Proteins 0.000 claims 1
- 102100022433 Single-stranded DNA cytosine deaminase Human genes 0.000 claims 1
- 102000005747 Transcription Factor RelA Human genes 0.000 claims 1
- 108010031154 Transcription Factor RelA Proteins 0.000 claims 1
- 102000004357 Transferases Human genes 0.000 claims 1
- 108090000992 Transferases Proteins 0.000 claims 1
- -1 VP64 Proteins 0.000 claims 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000003197 catalytic effect Effects 0.000 claims 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical class O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000001671 embryonic stem cell Anatomy 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 230000017156 mRNA modification Effects 0.000 claims 1
- 210000001161 mammalian embryo Anatomy 0.000 claims 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims 1
- 210000001778 pluripotent stem cell Anatomy 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 102100034113 tRNA-specific adenosine deaminase 1 Human genes 0.000 claims 1
- 102100034045 tRNA-specific adenosine deaminase 2 Human genes 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024080681A JP2024112895A (ja) | 2017-08-23 | 2024-05-17 | 変更されたＰＡＭ特異性を有する遺伝子操作されたＣＲＩＳＰＲ－Ｃａｓ９ヌクレアーゼ |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762549303P | 2017-08-23 | 2017-08-23 | |
| US62/549,303 | 2017-08-23 | ||
| US201862641687P | 2018-03-12 | 2018-03-12 | |
| US62/641,687 | 2018-03-12 | ||
| PCT/US2018/047577 WO2019040650A1 (en) | 2017-08-23 | 2018-08-22 | GENETICALLY MODIFIED CRISPR-CAS9 NUCLEASES HAVING MODIFIED PAM SPECIFICITY |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024080681A Division JP2024112895A (ja) | 2017-08-23 | 2024-05-17 | 変更されたＰＡＭ特異性を有する遺伝子操作されたＣＲＩＳＰＲ－Ｃａｓ９ヌクレアーゼ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020532967A JP2020532967A (ja) | 2020-11-19 |
| JP2020532967A5 true JP2020532967A5 (enExample) | 2021-09-30 |
| JP7581046B2 JP7581046B2 (ja) | 2024-11-12 |
Family
ID=65439890
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020511253A Active JP7581046B2 (ja) | 2017-08-23 | 2018-08-22 | 変更されたＰＡＭ特異性を有する遺伝子操作されたＣＲＩＳＰＲ－Ｃａｓ９ヌクレアーゼ |
| JP2024080681A Pending JP2024112895A (ja) | 2017-08-23 | 2024-05-17 | 変更されたＰＡＭ特異性を有する遺伝子操作されたＣＲＩＳＰＲ－Ｃａｓ９ヌクレアーゼ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024080681A Pending JP2024112895A (ja) | 2017-08-23 | 2024-05-17 | 変更されたＰＡＭ特異性を有する遺伝子操作されたＣＲＩＳＰＲ－Ｃａｓ９ヌクレアーゼ |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US11286468B2 (enExample) |
| EP (1) | EP3672612A4 (enExample) |
| JP (2) | JP7581046B2 (enExample) |
| CN (2) | CN111278450B (enExample) |
| AU (4) | AU2018320865B2 (enExample) |
| BR (1) | BR112020003596A2 (enExample) |
| CA (1) | CA3073448A1 (enExample) |
| WO (1) | WO2019040650A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9890364B2 (en) | 2012-05-29 | 2018-02-13 | The General Hospital Corporation | TAL-Tet1 fusion proteins and methods of use thereof |
| AU2015280069B2 (en) | 2014-06-23 | 2021-08-12 | The General Hospital Corporation | Genomewide unbiased identification of dsbs evaluated by sequencing (guide-seq) |
| EP3204496A1 (en) | 2014-10-10 | 2017-08-16 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
| AU2016226077B2 (en) | 2015-03-03 | 2021-12-23 | The General Hospital Corporation | Engineered CRISPR-Cas9 nucleases with altered PAM specificity |
| CA3000816A1 (en) | 2015-09-11 | 2017-03-16 | The General Hospital Corporation | Full interrogation of nuclease dsbs and sequencing (find-seq) |
| AU2017302551B2 (en) | 2016-07-26 | 2023-04-27 | The General Hospital Corporation | Variants of CRISPR from Prevotella and Francisella 1 (Cpf1) |
| EP3555297A1 (en) | 2016-12-19 | 2019-10-23 | Editas Medicine, Inc. | Assessing nuclease cleavage |
| WO2018129368A2 (en) | 2017-01-06 | 2018-07-12 | Editas Medicine, Inc. | Methods of assessing nuclease cleavage |
| WO2018195545A2 (en) | 2017-04-21 | 2018-10-25 | The General Hospital Corporation | Variants of cpf1 (cas12a) with altered pam specificity |
| US11499151B2 (en) | 2017-04-28 | 2022-11-15 | Editas Medicine, Inc. | Methods and systems for analyzing guide RNA molecules |
| CA3063733A1 (en) | 2017-05-25 | 2018-11-29 | The General Hospital Corporation | Base editors with improved precision and specificity |
| CN110997908A (zh) | 2017-06-09 | 2020-04-10 | 爱迪塔斯医药公司 | 工程化的cas9核酸酶 |
| EP3652312A1 (en) | 2017-07-14 | 2020-05-20 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
| WO2019040650A1 (en) | 2017-08-23 | 2019-02-28 | The General Hospital Corporation | GENETICALLY MODIFIED CRISPR-CAS9 NUCLEASES HAVING MODIFIED PAM SPECIFICITY |
| AU2019256287B2 (en) | 2018-04-17 | 2026-02-05 | The General Hospital Corporation | Sensitive in vitro assays for substrate preferences and sites of nucleic acid binding, modifying, and cleaving agents |
| KR102853088B1 (ko) * | 2018-05-11 | 2025-09-02 | 빔 테라퓨틱스, 인크. | 프로그래밍가능한 염기 편집기 시스템을 이용하여 단일염기다형성을 편집하는 방법 |
| WO2019217942A1 (en) | 2018-05-11 | 2019-11-14 | Beam Therapeutics Inc. | Methods of substituting pathogenic amino acids using programmable base editor systems |
| AU2019291918B2 (en) | 2018-06-29 | 2025-06-12 | Editas Medicine, Inc. | Synthetic guide molecules, compositions and methods relating thereto |
| EP3850088A4 (en) | 2018-09-07 | 2023-07-19 | Beam Therapeutics, Inc. | Compositions and methods for improving base editing |
| KR20210055733A (ko) | 2018-09-07 | 2021-05-17 | 빔 테라퓨틱스, 인크. | 핵염기 편집 시스템을 전달하기 위한 조성물 및 방법 |
| JP7646552B2 (ja) | 2019-01-31 | 2025-03-17 | ビーム セラピューティクス インク． | 低減された非標的脱アミノ化を有する核酸塩基エディターおよび核酸塩基エディターの特徴づけのためのアッセイ |
| WO2020163396A1 (en) | 2019-02-04 | 2020-08-13 | The General Hospital Corporation | Adenine dna base editor variants with reduced off-target rna editing |
| US12600971B2 (en) | 2019-02-13 | 2026-04-14 | Beam Therapeutics Inc. | Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence |
| WO2020168135A1 (en) | 2019-02-13 | 2020-08-20 | Beam Therapeutics Inc. | Compositions and methods for treating alpha-1 antitrypsin deficiency |
| CN114026226B (zh) * | 2019-04-26 | 2024-10-18 | 株式会社图尔金 | 靶特异性crispr突变体 |
| CN112266418A (zh) * | 2019-07-08 | 2021-01-26 | 中国科学院微生物研究所 | 改进的基因组编辑系统及其应用 |
| CN117264998A (zh) * | 2019-07-10 | 2023-12-22 | 苏州齐禾生科生物科技有限公司 | 双功能基因组编辑系统及其用途 |
| CN119913134A (zh) * | 2019-08-29 | 2025-05-02 | 比姆医疗股份有限公司 | 用于编辑突变以允许转录或表达的组合物和方法 |
| US20220290121A1 (en) * | 2019-08-30 | 2022-09-15 | The General Hospital Corporation | Combinatorial Adenine and Cytosine DNA Base Editors |
| CA3153563A1 (en) * | 2019-09-09 | 2021-03-18 | Beam Therapeutics Inc. | Novel crispr enzymes, methods, systems and uses thereof |
| US12594301B2 (en) | 2019-09-27 | 2026-04-07 | Beam Therapeutics Inc. | Compositions and methods for treatment of liquid cancers |
| KR102421129B1 (ko) * | 2019-10-14 | 2022-07-15 | 연세대학교 산학협력단 | 신규 프로토스페이서 인접 모티프 서열 및 이를 이용한 세포의 유전체에서 표적 핵산을 변형시키는 방법 |
| EP4093864A4 (en) * | 2020-01-24 | 2024-04-10 | The General Hospital Corporation | Unconstrained genome targeting with near-pamless engineered crispr-cas9 variants |
| WO2021151085A2 (en) | 2020-01-24 | 2021-07-29 | The General Hospital Corporation | Crispr-cas enzymes with enhanced on-target activity |
| BR112022017715A2 (pt) | 2020-03-04 | 2022-11-16 | Flagship Pioneering Innovations Vi Llc | Métodos e composições para modular um genoma |
| AU2021347359A1 (en) | 2020-09-25 | 2023-05-18 | Beam Therapeutics Inc. | Fratricide resistant modified immune cells and methods of using the same |
| CN112430613A (zh) * | 2020-12-08 | 2021-03-02 | 安徽省农业科学院水稻研究所 | 一种宽编辑范围的SpG基因及其应用 |
| WO2022152746A1 (en) | 2021-01-13 | 2022-07-21 | Alia Therapeutics Srl | K526d cas9 variants and applications thereof |
| CA3231712A1 (en) | 2021-09-08 | 2023-03-16 | Flagship Pioneering Innovations Vi, Llc | Pah-modulating compositions and methods |
| KR20260037664A (ko) | 2021-09-08 | 2026-03-18 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | 게놈을 조절하기 위한 방법 및 조성물 |
| CN116286736B (zh) * | 2022-01-17 | 2026-05-01 | 四川大学 | 一种具有扩大的pam识别范围的融合蛋白及其应用 |
| KR20260094824A (ko) * | 2023-10-25 | 2026-06-23 | 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 | 고효율, 저오프타겟 유전자 편집 도구 |
| WO2025158391A2 (en) * | 2024-01-24 | 2025-07-31 | The General Hospital Corporation | Generation of custom crispr-cas9 pam variant enzymes |
| CN118048343B (zh) * | 2024-03-01 | 2025-01-28 | 上海交通大学 | Cas9核酸酶及其制备方法和用途 |
| CN120005854B (zh) * | 2025-04-18 | 2025-08-05 | 广州瑞风生物科技有限公司 | Cas9突变体、基因编辑系统及应用 |
Family Cites Families (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2380993B1 (en) | 2004-03-08 | 2015-12-23 | Rubicon Genomics, Inc. | Method for generating and amplifying DNA libraries for sensitive detection and analysis of DNA methylation |
| WO2007145612A1 (en) | 2005-06-06 | 2007-12-21 | 454 Life Sciences Corporation | Paired end sequencing |
| DK1924704T3 (da) | 2005-08-02 | 2011-09-05 | Rubicon Genomics Inc | Sammensætninger og fremgangsmåder til bearbejdning og mangfoldiggørelse af DNA, herunder ved anvendelse af flere enzymer i en enkelt reaktion |
| EP2325332B1 (en) | 2005-08-26 | 2012-10-31 | DuPont Nutrition Biosciences ApS | Use of CRISPR associated genes (CAS) |
| KR20080075107A (ko) | 2005-11-11 | 2008-08-14 | 화이자 인코포레이티드 | 면역조절성 올리고데옥시뉴클레오티드를 사용하는 조합물및 방법 |
| MX2009009071A (es) | 2007-03-02 | 2009-09-24 | Danisco | Cultivos con resistencia mejorada a fagos. |
| EP2183360B1 (en) | 2007-08-30 | 2017-01-11 | Hadasit Medical Research Services&Development Company Ltd. | Nucleic acid sequences comprising nf-(kappa)b binding site within o(6)-methylguanine-dna-methyltransferase (mgmt) promoter region and uses thereof for the treatment of cancer and immune-related disorders |
| WO2009133466A2 (en) | 2008-04-30 | 2009-11-05 | Population Genetics Technologies Ltd. | Asymmetric adapter library construction |
| US8546553B2 (en) | 2008-07-25 | 2013-10-01 | University Of Georgia Research Foundation, Inc. | Prokaryotic RNAi-like system and methods of use |
| US8383345B2 (en) | 2008-09-12 | 2013-02-26 | University Of Washington | Sequence tag directed subassembly of short sequencing reads into long sequencing reads |
| US20100076057A1 (en) | 2008-09-23 | 2010-03-25 | Northwestern University | TARGET DNA INTERFERENCE WITH crRNA |
| WO2010054108A2 (en) | 2008-11-06 | 2010-05-14 | University Of Georgia Research Foundation, Inc. | Cas6 polypeptides and methods of use |
| EP2367938B1 (en) | 2008-12-12 | 2014-06-11 | DuPont Nutrition Biosciences ApS | Genetic cluster of strains of streptococcus thermophilus having unique rheological properties for dairy fermentation |
| JP5387839B2 (ja) | 2009-09-04 | 2014-01-15 | アイシン・エィ・ダブリュ株式会社 | ナビゲーション装置、ナビゲーション方法、及びナビゲーションプログラム |
| US9023769B2 (en) | 2009-11-30 | 2015-05-05 | Complete Genomics, Inc. | cDNA library for nucleic acid sequencing |
| WO2011086118A1 (en) | 2010-01-14 | 2011-07-21 | Deutsches Krebsforschungszentrum | In vivo determination of the lokalization of dna double-stand breaks and application thereof |
| US9255259B2 (en) | 2010-02-09 | 2016-02-09 | Sangamo Biosciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
| US10087431B2 (en) | 2010-03-10 | 2018-10-02 | The Regents Of The University Of California | Methods of generating nucleic acid fragments |
| CA2798703A1 (en) | 2010-05-10 | 2011-11-17 | The Regents Of The University Of California | Endoribonuclease compositions and methods of use thereof |
| EP3702460A1 (en) | 2010-11-12 | 2020-09-02 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
| US20140201857A1 (en) | 2013-01-14 | 2014-07-17 | Recombinetics, Inc. | Hornless livestock |
| US20140113376A1 (en) | 2011-06-01 | 2014-04-24 | Rotem Sorek | Compositions and methods for downregulating prokaryotic genes |
| WO2013066438A2 (en) | 2011-07-22 | 2013-05-10 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| WO2013078470A2 (en) | 2011-11-22 | 2013-05-30 | MOTIF, Active | Multiplex isolation of protein-associated nucleic acids |
| GB201122458D0 (en) | 2011-12-30 | 2012-02-08 | Univ Wageningen | Modified cascade ribonucleoproteins and uses thereof |
| US9528107B2 (en) | 2012-01-31 | 2016-12-27 | Pacific Biosciences Of California, Inc. | Compositions and methods for selection of nucleic acids |
| US9637739B2 (en) | 2012-03-20 | 2017-05-02 | Vilnius University | RNA-directed DNA cleavage by the Cas9-crRNA complex |
| EP4026912A1 (en) | 2012-05-10 | 2022-07-13 | The General Hospital Corporation | Methods for determining a nucleotide sequence |
| ES2728782T3 (es) | 2012-05-25 | 2019-10-28 | Univ California | Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN |
| CA2877094A1 (en) | 2012-06-18 | 2013-12-27 | Nugen Technologies, Inc. | Compositions and methods for negative selection of non-desired nucleic acid sequences |
| US20140024542A1 (en) | 2012-07-17 | 2014-01-23 | Counsyl, Inc. | Methods and compositions for enrichment of target polynucleotides |
| AU2012385961B9 (en) | 2012-07-24 | 2017-05-18 | Natera, Inc. | Highly multiplex PCR methods and compositions |
| EP2914745B1 (en) | 2012-11-05 | 2017-09-06 | Rubicon Genomics, Inc. | Barcoding nucleic acids |
| EP3064585B1 (en) | 2012-12-12 | 2020-02-05 | The Broad Institute, Inc. | Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation |
| WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
| SG10201707569YA (en) | 2012-12-12 | 2017-10-30 | Broad Inst Inc | Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications |
| KR102955556B1 (ko) | 2012-12-12 | 2026-04-22 | 더 브로드 인스티튜트, 인코퍼레이티드 | 서열 조작을 위한 crispr-cas 성분 시스템, 방법 및 조성물 |
| CN105209621B (zh) | 2012-12-12 | 2021-05-25 | 布罗德研究所有限公司 | 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化 |
| PT2931898E (pt) | 2012-12-12 | 2016-06-16 | Harvard College | Manipulação e otimização de sistemas, métodos e composições para manipulação de sequências com domínios funcionais |
| MX380562B (es) | 2012-12-12 | 2025-03-12 | Broad Inst Inc | Modificaciones de sistemas, métodos y composiciones guía optimizadas para la manipulación de secuencias. |
| EP2931899A1 (en) | 2012-12-12 | 2015-10-21 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| CA2893579A1 (en) | 2012-12-13 | 2014-06-19 | Dow Agrosciences Llc | Dna detection methods for site specific nuclease activity |
| US20140212869A1 (en) | 2013-01-25 | 2014-07-31 | Agilent Technologies, Inc. | Nucleic Acid Proximity Assay Involving the Formation of a Three-way junction |
| EP2954042B1 (en) | 2013-02-07 | 2017-12-06 | The General Hospital Corporation | Tale transcriptional activators |
| US10227610B2 (en) | 2013-02-25 | 2019-03-12 | Sangamo Therapeutics, Inc. | Methods and compositions for enhancing nuclease-mediated gene disruption |
| ES2749624T3 (es) | 2013-03-14 | 2020-03-23 | Caribou Biosciences Inc | Composiciones y métodos de ácidos nucleicos dirigidos a ácido nucleico |
| US9234213B2 (en) | 2013-03-15 | 2016-01-12 | System Biosciences, Llc | Compositions and methods directed to CRISPR/Cas genomic engineering systems |
| US20140349400A1 (en) | 2013-03-15 | 2014-11-27 | Massachusetts Institute Of Technology | Programmable Modification of DNA |
| US10760064B2 (en) | 2013-03-15 | 2020-09-01 | The General Hospital Corporation | RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci |
| US20140273230A1 (en) | 2013-03-15 | 2014-09-18 | Sigma-Aldrich Co., Llc | Crispr-based genome modification and regulation |
| CN105408483A (zh) | 2013-03-15 | 2016-03-16 | 通用医疗公司 | 遗传和表观遗传调节蛋白至特定基因组基因座的rna引导的靶向 |
| US11332719B2 (en) | 2013-03-15 | 2022-05-17 | The Broad Institute, Inc. | Recombinant virus and preparations thereof |
| CN105263312A (zh) | 2013-04-05 | 2016-01-20 | 美国陶氏益农公司 | 用于在植物基因组内整合外源序列的方法和组合物 |
| DK3456831T3 (da) | 2013-04-16 | 2021-09-06 | Regeneron Pharma | Målrettet modifikation af rottegenom |
| US10604771B2 (en) | 2013-05-10 | 2020-03-31 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
| EP3004339B1 (en) | 2013-05-29 | 2021-07-07 | Cellectis | New compact scaffold of cas9 in the type ii crispr system |
| ES2777217T3 (es) | 2013-06-17 | 2020-08-04 | Broad Inst Inc | Suministro, modificación y optimización de sistemas de guía en tándem, métodos y composiciones para la manipulación de secuencias |
| WO2014204725A1 (en) | 2013-06-17 | 2014-12-24 | The Broad Institute Inc. | Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation |
| EP3022304B1 (en) | 2013-07-19 | 2018-12-26 | Larix Biosciences LLC | Methods and compositions for producing double allele knock outs |
| US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| CN105917002A (zh) | 2013-11-18 | 2016-08-31 | 鲁比康基因组学公司 | 用于减少背景的可降解适体 |
| JP6793547B2 (ja) | 2013-12-12 | 2020-12-02 | ザ・ブロード・インスティテュート・インコーポレイテッド | 最適化機能ＣＲＩＳＰＲ−Ｃａｓ系による配列操作のための系、方法および組成物 |
| WO2015089473A1 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation |
| WO2015089364A1 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Crystal structure of a crispr-cas system, and uses thereof |
| HUE058149T2 (hu) | 2014-01-31 | 2022-07-28 | Swift Biosciences Inc | Javított eljárások DNS-szubsztrátok feldolgozására |
| AU2015280069B2 (en) | 2014-06-23 | 2021-08-12 | The General Hospital Corporation | Genomewide unbiased identification of dsbs evaluated by sequencing (guide-seq) |
| AU2016206870B2 (en) | 2015-01-12 | 2022-02-17 | Massachusetts Institute Of Technology | Gene editing through microfluidic delivery |
| MA41349A (fr) | 2015-01-14 | 2017-11-21 | Univ Temple | Éradication de l'herpès simplex de type i et d'autres virus de l'herpès associés guidée par arn |
| AU2016226077B2 (en) | 2015-03-03 | 2021-12-23 | The General Hospital Corporation | Engineered CRISPR-Cas9 nucleases with altered PAM specificity |
| US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| EP3929287A3 (en) | 2015-06-18 | 2022-04-13 | The Broad Institute, Inc. | Crispr enzyme mutations reducing off-target effects |
| WO2017015015A1 (en) | 2015-07-17 | 2017-01-26 | Emory University | Crispr-associated protein from francisella and uses related thereto |
| US9926546B2 (en) | 2015-08-28 | 2018-03-27 | The General Hospital Corporation | Engineered CRISPR-Cas9 nucleases |
| US9512446B1 (en) | 2015-08-28 | 2016-12-06 | The General Hospital Corporation | Engineered CRISPR-Cas9 nucleases |
| WO2017040348A1 (en) | 2015-08-28 | 2017-03-09 | The General Hospital Corporation | Engineered crispr-cas9 nucleases |
| CA3000816A1 (en) | 2015-09-11 | 2017-03-16 | The General Hospital Corporation | Full interrogation of nuclease dsbs and sequencing (find-seq) |
| CA3000762A1 (en) | 2015-09-30 | 2017-04-06 | The General Hospital Corporation | Comprehensive in vitro reporting of cleavage events by sequencing (circle-seq) |
| WO2017070632A2 (en) * | 2015-10-23 | 2017-04-27 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
| EP3845668A1 (en) | 2015-10-30 | 2021-07-07 | New England Biolabs, Inc. | Compositions and methods for determining modified cytosines by sequencing |
| CA3004310A1 (en) | 2015-11-04 | 2017-05-11 | Atreca, Inc. | Combinatorial sets of nucleic acid barcodes for analysis of nucleic acids associated with single cells |
| US11566052B2 (en) | 2015-11-11 | 2023-01-31 | Lonza Ltd. | CRISPR-associated (Cas) proteins with reduced immunogenicity |
| US9896696B2 (en) | 2016-02-15 | 2018-02-20 | Benson Hill Biosystems, Inc. | Compositions and methods for modifying genomes |
| CN105543195A (zh) * | 2016-03-01 | 2016-05-04 | 中国水稻研究所 | 植物Cas9变体蛋白VQR及其编码基因与应用 |
| KR20260004568A (ko) | 2016-04-19 | 2026-01-08 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신규한 crispr 효소 및 시스템 |
| CN109312386B (zh) * | 2016-06-15 | 2022-10-25 | 株式会社图尔金 | 使用中靶靶标和脱靶靶标的多重靶标系统筛选靶特异性核酸酶的方法及其用途 |
| WO2018027078A1 (en) | 2016-08-03 | 2018-02-08 | President And Fellows Of Harard College | Adenosine nucleobase editors and uses thereof |
| WO2018052247A1 (ko) | 2016-09-13 | 2018-03-22 | 주식회사 툴젠 | 시토신 디아미나제에 의한 dna에서의 염기 교정 확인 방법 |
| US11242542B2 (en) | 2016-10-07 | 2022-02-08 | Integrated Dna Technologies, Inc. | S. pyogenes Cas9 mutant genes and polypeptides encoded by same |
| WO2018068053A2 (en) | 2016-10-07 | 2018-04-12 | Integrated Dna Technologies, Inc. | S. pyogenes cas9 mutant genes and polypeptides encoded by same |
| WO2018074979A1 (en) | 2016-10-17 | 2018-04-26 | Nanyang Technological University | Truncated crispr-cas proteins for dna targeting |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| CA3063733A1 (en) | 2017-05-25 | 2018-11-29 | The General Hospital Corporation | Base editors with improved precision and specificity |
| US11371030B2 (en) * | 2017-05-31 | 2022-06-28 | The University Of Tokyo | Modified Cas9 protein and use thereof |
| US20200140835A1 (en) | 2017-06-06 | 2020-05-07 | The General Hospital Corporation | Engineered CRISPR-Cas9 Nucleases |
| US11441135B2 (en) | 2017-07-07 | 2022-09-13 | Toolgen Incorporated | Target-specific CRISPR mutant |
| WO2019040650A1 (en) | 2017-08-23 | 2019-02-28 | The General Hospital Corporation | GENETICALLY MODIFIED CRISPR-CAS9 NUCLEASES HAVING MODIFIED PAM SPECIFICITY |
| WO2019075197A1 (en) | 2017-10-11 | 2019-04-18 | The General Hospital Corporation | METHODS OF DETECTION OF INDIVIDUAL SITE-SPECIFIC PARASITE GENOMIC DEAMINATION BY BASE EDITING TECHNOLOGIES |
| EP3707252A1 (en) | 2017-11-10 | 2020-09-16 | Novozymes A/S | Temperature-sensitive cas9 protein |
| AU2019256287B2 (en) | 2018-04-17 | 2026-02-05 | The General Hospital Corporation | Sensitive in vitro assays for substrate preferences and sites of nucleic acid binding, modifying, and cleaving agents |
| KR102853088B1 (ko) | 2018-05-11 | 2025-09-02 | 빔 테라퓨틱스, 인크. | 프로그래밍가능한 염기 편집기 시스템을 이용하여 단일염기다형성을 편집하는 방법 |
| WO2020041751A1 (en) | 2018-08-23 | 2020-02-27 | The Broad Institute, Inc. | Cas9 variants having non-canonical pam specificities and uses thereof |
| WO2021042047A1 (en) | 2019-08-30 | 2021-03-04 | The General Hospital Corporation | C-to-g transversion dna base editors |
| WO2021151085A2 (en) | 2020-01-24 | 2021-07-29 | The General Hospital Corporation | Crispr-cas enzymes with enhanced on-target activity |
| EP4093864A4 (en) | 2020-01-24 | 2024-04-10 | The General Hospital Corporation | Unconstrained genome targeting with near-pamless engineered crispr-cas9 variants |
-
2018
- 2018-08-22 WO PCT/US2018/047577 patent/WO2019040650A1/en not_active Ceased
- 2018-08-22 US US16/109,657 patent/US11286468B2/en active Active
- 2018-08-22 CN CN201880068905.9A patent/CN111278450B/zh active Active
- 2018-08-22 AU AU2018320865A patent/AU2018320865B2/en active Active
- 2018-08-22 EP EP18848977.7A patent/EP3672612A4/en active Pending
- 2018-08-22 CA CA3073448A patent/CA3073448A1/en active Pending
- 2018-08-22 CN CN202410333226.7A patent/CN118530967A/zh active Pending
- 2018-08-22 JP JP2020511253A patent/JP7581046B2/ja active Active
- 2018-08-22 BR BR112020003596-3A patent/BR112020003596A2/pt unknown
-
2022
- 2022-02-17 US US17/674,558 patent/US11624058B2/en active Active
-
2023
- 2023-02-24 US US18/174,294 patent/US12241096B2/en active Active
- 2023-12-07 AU AU2023278074A patent/AU2023278074B2/en active Active
-
2024
- 2024-05-17 JP JP2024080681A patent/JP2024112895A/ja active Pending
-
2025
- 2025-12-03 AU AU2025275152A patent/AU2025275152B2/en active Active
-
2026
- 2026-06-11 AU AU2026204470A patent/AU2026204470A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023278074B2 (en) | Engineered CRISPR-Cas9 nucleases with altered PAM specificity | |
| ES3055163T3 (en) | Class ii, type ii crispr systems | |
| Liu et al. | Expanding the CRISPR toolbox in zebrafish for studying development and disease | |
| JP2023011629A (ja) | 核酸塩基エディターのａａｖ送達 | |
| JP2024138268A (ja) | プログラム可能な塩基エディターシステムを用いて単一ヌクレオチド多型を編集する方法 | |
| Lone et al. | CRISPR/Cas9 system: a bacterial tailor for genomic engineering | |
| JP2020510439A5 (enExample) | ||
| Shirodkar et al. | Epigenetics in cardiovascular disease | |
| JP2020164529A (ja) | 遺伝子編集用のｃａｓ多様体 | |
| JP2016512691A5 (enExample) | ||
| Minarovits et al. | Epigenetic regulation | |
| AU2014281026A1 (en) | Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation | |
| AU2016316845A1 (en) | Engineered CRISPR-Cas9 nucleases | |
| JP2023540493A (ja) | Ｒｎａ誘導型ｒｎａターゲティングｃｒｉｓｐｒエフェクターのための系、方法及び組成物 | |
| WO2020173150A1 (zh) | 单碱基编辑导致非靶向单核苷酸变异及避免该变异的高特异性无脱靶单碱基基因编辑工具 | |
| Yoo et al. | Dissecting tissue-specific super-enhancers by integrating genome-wide analyses and CRISPR/Cas9 genome editing | |
| WO2024259295A2 (en) | Reprogrammable fanzor polynucleotides and uses thereof | |
| Jurkowska et al. | Silencing of gene expression by targeted DNA methylation: concepts and approaches | |
| Zimmerman et al. | Enhancement of transgene expression by nuclear transcription factor Y and CCCTC‐binding factor | |
| Rasmussen | The epigenetics of early development: inferences from stem cells | |
| Ramos-Hernández et al. | Donor insertion into CX3CR1 allows epigenetic modulation of a constitutive promoter on hematopoietic stem cells and its activation upon myeloid differentiation | |
| Zimmerman et al. | Enhancement of Transgene Expression by NF-Y and CTCF | |
| Rohm | CRISPR/dCas9-Based Tools for Epigenome Editing | |
| Sinha | Effects of the H3. 3 K36M Oncohistone on the Dynamics of Gene Silencing and Epigenetic Memory | |
| Enríquez | Epigenome Editing |